Literature DB >> 7750557

Use of site-directed antibodies to probe the topography of the alpha 2 subunit of voltage-gated Ca2+ channels.

K Brickley1, V Campbell, N Berrow, R Leach, R I Norman, D Wray, A C Dolphin, S A Baldwin.   

Abstract

Polyclonal antibodies were raised against peptides corresponding to residues 1-15, 469-483 and 933-951 of the rabbit skeletal muscle L-type calcium channel alpha 2/delta primary translation product, for use as topological probes. Immunocytochemical comparison of the abilities of the antibodies to bind to the alpha 2 and delta subunits in intact and detergent-permeabilised rat dorsal root ganglion cells enabled the membrane orientation of these regions to be established. The resultant data indicate that the regions containing residues 1-15 and 469-483 of the alpha 2 subunit, and residues 1-17 of the delta subunit, are exposed on the extracellular surface of the membrane, findings consistent with a model that proposes alpha 2 to be entirely extracellular.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750557     DOI: 10.1016/0014-5793(95)00371-f

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  The effect of alpha2-delta and other accessory subunits on expression and properties of the calcium channel alpha1G.

Authors:  A C Dolphin; C N Wyatt; J Richards; R E Beattie; P Craig; J H Lee; L L Cribbs; S G Volsen; E Perez-Reyes
Journal:  J Physiol       Date:  1999-08-15       Impact factor: 5.182

2.  Differential plasma membrane targeting of voltage-dependent calcium channel subunits expressed in a polarized epithelial cell line.

Authors:  N L Brice; A C Dolphin
Journal:  J Physiol       Date:  1999-03-15       Impact factor: 5.182

Review 3.  Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere.

Authors:  Charles A Whittaker; Richard O Hynes
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

Review 4.  Targeting mechanisms of high voltage-activated Ca2+ channels.

Authors:  Stefan Herlitze; Mian Xie; Jing Han; Alexander Hümmer; Katya V Melnik-Martinez; Rosa L Moreno; Melanie D Mark
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 5.  Calcium channel alpha2delta subunits: differential expression, function, and drug binding.

Authors:  Norbert Klugbauer; Else Marais; Franz Hofmann
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

6.  The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2.

Authors:  Alexandra Tran-Van-Minh; Annette C Dolphin
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

7.  Targeted disruption of the voltage-dependent calcium channel alpha2/delta-1-subunit.

Authors:  Geraldine A Fuller-Bicer; Gyula Varadi; Sheryl E Koch; Masakazu Ishii; Ilona Bodi; Nijiat Kadeer; James N Muth; Gabor Mikala; Natalia N Petrashevskaya; Michael A Jordan; Sui-Po Zhang; Ning Qin; Christopher M Flores; Idit Isaacsohn; Maria Varadi; Yasuo Mori; W Keith Jones; Arnold Schwartz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

8.  Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding.

Authors:  M Wang; J Offord; D L Oxender; T Z Su
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

9.  The alpha2delta subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function.

Authors:  Anthony Davies; Ivan Kadurin; Anita Alvarez-Laviada; Leon Douglas; Manuela Nieto-Rostro; Claudia S Bauer; Wendy S Pratt; Annette C Dolphin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 10.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.